We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 735.00 | GBX |
Gw Pharmaceuticals (GWP) Share Charts1 Year Gw Pharmaceuticals Chart |
|
1 Month Gw Pharmaceuticals Chart |
Intraday Gw Pharmaceuticals Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/3/2021 | 12:28 | Moderated Thread | 9,113 |
| 13/3/2019 | 20:30 | MY 2 BIGGEST MULTI BAGGERS FOR 2006: NTX and GWP..10 bagger guranteed! | 16 |
| 02/4/2017 | 17:30 | TIME TO BAN SYNTHETIC MARIJUANA 'SYNDROS'..PEOPLE WANT THE REAL STUFF! | - |
| 02/12/2016 | 14:43 | Viewpoints on GW Pharmaceuticals (GWP) | 1 |
| 26/9/2016 | 17:25 | GW Pharma (GWP) Positive Epidiolex Trial Outcome | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 05/11/2018 21:26 by sojourno Funny how things pan out. I was in the middle of a house purchase and financial reorganisation so didn't buy a single share on this... I knew the Co read this BB... hope you all did well!!(Chuckle!) |
Posted at 31/10/2018 18:05 by harry hasta What is the corelation between shares in the UK company and the quoted Nasdaq ADR price? |
Posted at 02/10/2018 05:47 by wengerb Contact the company secretary of the UK part of GWP. |
Posted at 27/9/2018 18:44 by gwright1 I still have the original GWP share certificate. I seem to be getting nowhere trying to transfer to ADR. Does anyone know where I can go for some assistance?Help would be greatly appreciated |
Posted at 02/12/2016 11:29 by 123prezzie Wenger. Do you have a crystal ball to forecast a share price rise of 18x by May 2020 or are you using statistics in the same way as the directors? GWP floated in June 2001 at a price around 182p. Share price rise in 15 1/2 years is under 4x and I can find you any number of Biotech which have done better than this. The only way to get near 18x is to choose the all time low of 36p in Sept 2008 and you were a shareholder before then.My own realised gain is 8x from a significant investment built up between 2005 and 2009. I believed and am full of praise for the directors in managing to maintain their belief and raise money despite almost zero revenue from product sales after nearly 20 years since start-up. There is a lot of emotional energy emanating from GWP's supporters. I am not belittling the enormous effort required by the Board to get here, I am just trying to look rationally at matters whilst deciding whether to reinvest. The present upheaval seems to be making others rethink as well. |
Posted at 11/11/2016 18:44 by pj84 Finally received the corporate action details from Hargreaves Lansdown (copy below for info.) and have completed a very simple process to elect to convert my shares to ADR's and will await the conversion and glad to be able to retain my holding in my SIPP."What is happening? The Board of GW Pharmaceuticals plc has announced proposals to cancel the Company’s Ordinary Shares from trading on AIM (Alternative Investment Market). It is expected that the Company’s Shares will be delisted with effect from the close of business on 2 December 2016. Why is this happening? The Company has announced “The Company’s Ordinary Shares were admitted to trading on AIM in 2001. AIM provided GW with important access to capital and share trading liquidity during the formative phase of its business, enabling the Company to invest in and develop the cannabinoid technology platform upon which its pipeline of future medicines relies. In May 2013, the Company completed a successful initial public offering (or IPO) of ADRs on NASDAQ, with the result that dual-listed status was achieved. The liquidity of trading of GW’s Ordinary Shares was immediately enhanced by the NASDAQ listing and demand from US investors has led to a rapid increase in the proportion of GW’s Ordinary Shares that are held as ADRs and traded via NASDAQ. At the date of this letter 78% of Ordinary Shares are held in ADR form and over 94% of shares traded in the last six months were traded in the form of ADRs on NASDAQ. “The Directors believe that if the Ordinary Shares were to continue to be admitted to trading on AIM the trend towards the holding of Ordinary Shares in ADR form and growth in the proportion of trading in ADR form on NASDAQ would continue, leading to a further reduction in the proportion of Ordinary Shares traded on AIM. The Directors believe that a continuation of the decline in the proportion of shares traded on AIM would be likely to lead to a decrease in the liquidity of AIM trading and that it would therefore be advantageous for all Shareholders to combine trading volumes from both markets onto a single exchange. The Directors further believe that the AIM Delisting will: “Further enhance the liquidity of trading in the Company’s ADRs by combining on NASDAQ the volume of transactions from both NASDAQ and AIM. “Reduce the risks and costs associated with compliance with two different sets of market regulations and administrative practices. “Simplify day-to-day administration, allowing management to focus more time on the Group’s core business activities at this important stage of its development; “Reduce administrative expenses associated with maintaining the AIM quotation. “Accordingly, the Directors believe that it is no longer in the best interests of the Company or its Shareholders as a whole for the Company to retain its AIM quotation.” (Source: Company Announcement). What action do I need to take? If you wish to sell your holding before the proposed listing cancellation you must do so before 4.30pm 2 December 2016. The trade will be placed in accordance with our terms and conditions and subject to the standard Stockbrokers commission rates. To sell these Shares please phone us on 0117 980 9800 or deal online. Please note that if the cash consideration of a sale does not exceed the commission payable then the sale will not be executed. Please note that although Hargreaves Lansdown will endeavor to sell your Shares it may not be possible to sell all, or even any, of your Shares if a market for the Shares no longer exists. If you wish to maintain your holding of Ordinary Shares you need take no action. You should note that following the cancellation you may have difficulty selling this investment at a reasonable price and, in some circumstances, it may be impossible to sell it at any price. Important information for holders of GW Pharmaceuticals plc Shares within a Stocks & Shares ISA Please note, under HMRC rules unlisted Shares are not eligible to be held within a Stocks & Shares ISA. As a result any holding of GW Pharmaceuticals plc Shares within a Vantage Stocks & Shares ISA will need to be removed within 30 days of the effective date of the delisting (3 January 2017). Can I convert my Ordinary Shares to ADRs? Shareholders have the option to convert their Ordinary Shares to ADRs (American Depository Receipts) that will continue to trade on NASDAQ in the US. If you wish to convert your Ordinary Shares into ADRs you will need to give an instruction before our deadline of noon Tuesday 22 November 2016. You can give an instruction to convert your Shares online at www.hl.co.uk. Please log in to your account and click on your Vantage SIPP in the ‘My Accounts’ section of our website. Please select the dark blue Corporate Actions Icon alongside GW Pharmaceuticals plc Shares and follow the instructions provided. Alternatively you can give an instruction over the telephone on 0117 900 9000 after confirmation of your master password. Each ADR represents 12 GW Pharmaceuticals Ordinary Shares, as such the conversion has to take place in multiples of 12 and it is not possible to receive a fraction of an ADR. Any holdings not in multiples of 12 will receive a fractional cash payment. In order to complete the conversion the new ADRs will initially be deposited into our DTC account with our third party custodian, HSBC. They will then be transferred to our account with CREST (the UK Settlement System) allowing us to trade and settle the ADRs in the UK. Please note there may be a delay before we are able to trade the ADRs while we transfer the ADRs to CREST. Trades in ADRS will be settled in US Dollars in accordance with our Overseas Stockbroking terms and conditions. Please note, under HMRC rules the ADRs will be unable to be held within a Stocks & Shares ISA as the underlying holding will not be listed on a recognised stock exchange. As a result any holding of GW Pharmaceuticals plc ADRs within a Vantage Stocks & Shares ISA will need to be removed within 30 days of the conversion. Other information and warnings Should you have any queries relating to the Delisting please contact us on 0117 980 9912. Please note, we can provide factual assistance but cannot provide advice about which option you should choose. We hope you are satisfied with our service. If you would like to set up new products, or transfer other assets you hold to Hargreaves Lansdown please go to www.hl.co.uk or call our Investment Helpdesk on 0117 900 9000." |
Posted at 24/10/2016 20:29 by zlotini The problem with rumoured takeovers, I think, is how much weight, if any, to place on what often turns out to be speculation fuelled by a player seeking an unfair advantage. Today’s AT&T takeover offer for Time Warner is a reminder that takeover noise swirling in the market can be spot on. Can there be smoke without fire? Yes.With regards to GWP, it does seem odd that a few predators are ready to pounce. If GWP were already a takeover target, then it seemingly would make more sense that others would want to strike. I have made a feeble attempt to see if the takeover talk about GWP generated excess trading volumes on Nasdaq. But I find I am totally overwhelmed by the sheer number of shares traded on even normal days without takeover speculation driving the trades. At this stage, I place no premium on the share price because of takeover rumours. That is not to say the market does not. Does anyone know? Any premium that arose because of a takeover offer would be viewed by me as an unexpected huge bonus. I am incapable of placing/working out a realistic fundamental value for GWP shares - I have not done my homework and, anyway, would probably be incapable of doing it. I presently rely on the thread, articles and analysts’ research to provide guidance on the company’s prospects and its share price. It seems to me that GWP shares are still attractively priced even if the market has built a significant takeover premium, which I doubt, into the share price. |
Posted at 24/10/2016 18:43 by zlotini nodding it is interesting to see that the last day GWP shares, December 2, can be traded on Aim is the same day Q1 results were released last year. Management may want to take use the results presentation (likely to around December 2) as an opportunity to extol the virtues of having only a primary Nasdaq listing. Perhaps, this, or some other factor, has motivated/blinded GWP to give too short notice to certain shareholders who want to arrange timeously that their financial affairs remain highly tax efficient once the Aim listing ends. Oddly, the share price has suffered from a bout of pronounced weakness since the announcement that a new share structure will be in place shortly.I agree with Wenger that the sole listing on Nasdaq is not to facilitate an imminent takeover of GWP, although it would have that affect if it were ever taken over. I am not expecting any noise from management on Q1 results day about the rumoured long-line of predators waiting to pounce. If any first contact, or should I say first contacts, has/have been made, they are likely to be weak, given the cone of silence surrounding management. Perhaps, the journalist who alerted the investing world about the burgeoning takeover interest in GWP was confused by the signals emitting from his impeccable sources. There is always the distinct possibility that GWP is talking to various parties about joint venture funding for the development of a particular product. Yet to see confirmation that GWP has specifically appointed a M&A advisor. |
Posted at 05/10/2016 12:58 by zlotini I was about to post this view – written in a word document- and then saw Random’s post. But I decided to post it anyway.Greetings, especially to long-time posters and those I have met personally. I echo FF’s sentiments about the thread. Indeed, thanks to the superb contributions of several posters, I have been able to remain in touch, well-informed, about GWP’s progress and development without doing any research/work myself. It has worked well for me even though I only have a fraction of the holding I once had – given the current share price I can still reasonably happily celebrate the company’s seemingly great success. After becoming deliriously greedy, acknowledgement to nodding, I find I have become somewhat puzzled (deliriously confused most probably) about the recent takeover stuff. This has prompted me to do a little digging which could well be wide of the mark because I have missed what is staring me in the face. I would much appreciate some enlightenment/guidan I can find no RNS about the supposed M&A reported interest, or for that matter the appointment of Morgan Stanley as an advisor, particularly related to this new development. Personally, I think management is correct to say nothing about rumoured/reported takeover interest from several companies. Assuming this is the case (rumoured) no official announcement/acknowl I assume that Morgan Stanley was appointed as M&A advisor. Is it possible that this appointment was, perhaps, just good business practice rather than because specific approaches have been made to the company? By the way, Jim Cramer, the CNBC madman, a couple of weeks ago suggested that Gilead should acquire GWP. On the share price front, is there really a big premium already built into the price because of heightened takeover interest? Only now is the share price back to previous US$ highs. Of course, it is much past its previous high in sterling terms, thanks to the pound’s Brexit plunge. But back then, investors still did not have positive confirmation of positive trial results. Yes, US biotech shares have been a bit out of favour this year. On the other hand, the sector managed a rise of around 13%, one of the best performing sectors in the US market, in the last quarter despite Mylan’s share price dive. Moreover, no that one can necessarily rely on them, several analysts have set their price targets a bit higher than the current price and that is without accounting for a takeover premium. |
Posted at 01/10/2016 11:08 by wengerb My advice? Adopt the brace position.Next week it'll be nearly a month since the story about "many" potential partners looking at GWP and the appointment of Morgan Stanley as advisor to GWP. As I've said, had there been no truth in the story then GWP would simply have had to issue a polite denial. Not to have done so would have been poor corporate governance and GWP prides itself on good governance. I think that talks are taking place. Then Stephen Wright sold a large line of shares so there couldn't have been a takeover issue as why would he sell knowing a higher price might be in prospect? But he sold before the pIII data and, if anyone had an inkling of the likely success of those trials, it would have been Stephen. So I feel we can rule out the Stephen Wright share sale factor. In my working life I had a few brushes with with M&A and I found that any approaches that had no hope were rejected almost immediately. GWP and Morgan Stanley have had nearly a month to explore what the Morgan Stanley analyst referred to as "strategic optionalities". I think we'll soon see an announcement that will either say that a deal is on or that there's no deal at present. The share price will then leap up or fall substantially. As a long-term holder of GWP shares the latter won't worry me too much as I expect the share price to considerably exceed current levels when the FDA approves Epidiolex next year. Lazy journalists have as yet guessed that the "many" potentially interested parties lay within those pharma that already have a relationship with GWP; Bayer, Otsuka, Almirall, Novartis etc. I don't know about Novartis but the other three seem most unlikely as they've all had their fingers burned by the disappointing performance of Sativex. Based on minutes of desk research, I have a contender and it's Pfizer. GWP has aimed itself at CNS diseases. Pfizer has the world's biggest CNS franchise with sales in 2014 of $8.1 billion. Epidiolex potentially threatens the current roster of antiepileptic drugs. Pfizer has the world's biggest selling epilepsy drug, Lyrica, with sales of $5.1 billion (although Lyrica is also prescribed for other conditions). Pfizer has run a phase I trial on Lyrica for refractory epilepsy in children. Lyrica has a list of side effects as long as your arm. Pfizer has recently decided not to make the strategic decison of splitting the company in two but, according to a leading analyst, Dr. Tim Anderson "the most likely path forward involves hunting for more acquisition targets". In August, Pfizer announced it was paying $14 billion to buy Medivation. It's buying a portfolio of experimental antibiotics and anti-fungal pills from AstraZeneca. In June, Pfizer bought Anacor Pharmaceuticals Inc. for $5.2 billion. The chances of my being right about Pfizer are pretty remote. Why adopt the brace position? Because GWP's favourite day for releasing big news is Monday. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
